Kratom (Mitragyna speciosa): worldwide issues.

  title={Kratom (Mitragyna speciosa): worldwide issues.},
  author={Surash Ramanathan and Christopher R. McCurdy},
  journal={Current Opinion in Psychiatry},
PURPOSE OF REVIEW To inform readers about the increasingly popular Western dietary supplement, kratom (Mitragyna speciosa) and how the products are available in the Western world compared with traditional Southeast Asian use. Kratom has been traditionally used for increasing stamina of outdoor laborers (farmers), mood enhancement, pain, and opium addiction. Interestingly, kratom has been reported to have a paradoxical effect in that stimulant feelings, and sedative feelings can be obtained… 
Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States
This report highlights how converging factors have led to a surge in interest in kratom as a potential harm reduction agent in the treatment of pain and opioid use disorder.
Evaluation of the Mitragynine Content, Levels of Toxic Metals and the Presence of Microbes in Kratom Products Purchased in the Western Suburbs of Chicago
Eight different kratom products were legally purchased from various “head”/”smoke” shops in the Western Suburbs of Chicago and tested for microbial burden, a panel of metals, and levels of the main psychoactive alkaloid mitragynine, indicating that they were derived from kratom.
Mitragyna Species as Pharmacological Agents: From Abuse to Promising Pharmaceutical Products
This narrative review highlights some aspects of this genus, including historical background and botanical origins, habitat, cultivation, its use in traditional medicine, phytochemistry, pharmacology and toxicity, abuse and addiction, legal issues, and the potential of Mitragyna species as pharmaceutical products.
A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects
Results suggest that MOR agonists with a G-protein efficacy profile similar to buprenorphine can be developed into opioids that are effective analgesics with greatly reduced liabilities.
Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories
The goal was to better understand kratom dosing, changes in routines, and perception of effects, including time to onset, duration, and variability of beneficial and adverse outcomes from use and cessation, to help inform the development of controlled observational and experimental studies needed to advance the public health understanding of kratom product use.


Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia
It is suggested that chronic kratom administration does not significantly impair social functioning of users in a natural context in Malaysia, despite being dependent on kratom for prolonged periods of time.
Current perspectives on the impact of Kratom use
It is notable that Kratom can cause herb–drug interactions, especially with other central nervous system -active substances, and consumers may be exposed to adulterated or contaminated products, especially if purchased through websites or the darknet.
Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract
The results obtained in drug-naïve mice demonstrate weak behavioral effects mediated via μ and λ opioid receptors, indicating that the analgesic effect is mediated via κ opioid receptors.
7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects
It is found that mitragynine is converted in vitro in both mouse and human liver preparations to the much more potent mu-opioid receptor agonist 7-hydroxymitagynine and that this conversion is mediated by cytochrome P450 3A isoforms.
Opioid receptors and legal highs: Salvia divinorum and Kratom
Both Kratom alkaloids are reported to activate supraspinal mu- and delta- opioid receptors, explaining their use by chronic narcotics users to ameliorate opioid withdrawal symptoms.